- Home
- VYNE vs SNSE Comparison
VYNE vs SNSE Comparison
Compare VYNE & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VYNE | SNSE |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 10.3M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VYNE | SNSE |
|---|---|---|
| Price | $0.59 | $9.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $72.50 |
| AVG Volume (30 Days) | ★ 14.9M | 81.5K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $524,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.29 | N/A |
| 52 Week Low | $0.28 | $5.00 |
| 52 Week High | $4.30 | $18.35 |
Technical Indicators
Market Signals| Indicator | VYNE | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 71.15 | 50.75 |
| Support Level | $0.56 | $8.50 |
| Resistance Level | $0.75 | $9.60 |
| Average True Range (ATR) | 0.05 | 0.74 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 57.48 | 72.91 |
Price Performance
Historical ComparisonAbout VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).